

Immediate Release

DIMERIX PRESENTS KEYNOTE SPEECH AT BIO CONNECTIONS AUSTRALIA

MELBOURNE, Australia, 29 July 2024: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in inflammatory disease, is pleased to advise that CEO and Managing Director, Dr Nina Webster, will be presenting as the keynote speaker at the 7th Annual Bio Connections Australia in Melbourne on 29 July 2024.

The conference brings together key industry stakeholders from across the biotech ecosystem and focuses on translating medical research into commercialisation, including drug discovery and development, early phase clinical trials and expediting partnering transactions. In keeping with this purpose, Dr Webster was asked to talk to "Positioning for Success in Australian Biotech" in context of Dimerix clinical development pathway and licensing transactions.

A copy of the presentation is attached.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster Dimerix Limited Chief Executive Officer & Managing Director Tel: +61 1300 813 321 E: investor@dimerix.com Rudi Michelson Monsoon Communications Tel: +61 3 9620 3333 Mob: +61 (0)411 402 737 E: rudim@monsoon.com.au

Follow us on LinkedIn and Twitter

Authorised for lodgement by the Board of the Company

—END—

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. Dimerix HQ 425 Smith St, Fitzroy 3065 Victoria, Australia T. 1300 813 321 E. info@dimerix.com



The Phase 3 study, which is titled "<u>Angiotensin II Type 1 Receptor (AT1R) & <u>C</u>hemokine Receptor 2 (CCR2) <u>T</u>argets for <u>Inflammatory Nephrosis</u>", or ACTION3 for short, is a pivotal (Phase 3), multi-centre, randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients will be randomized to receive either DMX200 (120 mg capsule twice daily) or placebo.</u>

The single Phase 3 trial in FSGS patients has interim analysis points built in that are designed to capture evidence of proteinuria and kidney function (eGFR slope) during the trial, aimed at generating sufficient evidence to support marketing approval.

Further information about the study can be found on ClinicalTrials.gov (Study Identifier: NCT05183646) or Australian New Zealand Clinical Trials Registry (ANZCTR) (Study Identifier ACTRN12622000066785).

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. Dimerix is currently focussed on developing its proprietary Phase 3 product candidate DMX-200 (QYTOVRA® in some territories), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-700 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

About DMX 200

DMX 200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker - the standard of care treatment for hypertension and kidney disease. DMX 200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042, in addition to any exclusivity period that may apply in key territories. In 2020, Dimerix completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease, following a successful Phase 2a trial in patients with a range of chronic kidney diseases in 2017. No significant adverse safety events were reported in any trial, and all studies resulted in encouraging data that could provide meaningful clinical outcomes for patients with kidney disease.

About FSGS

FSGS is a rare disease that attacks the kidney's filtering units, where blood is cleaned (called the 'glomeruli'), causing irreversible scarring. This leads to permanent kidney damage and eventual end-stage failure of the organ, requiring dialysis or transplantation. For those diagnosed with FSGS the prognosis is not good. The average time from a diagnosis of FSGS to the onset of complete kidney failure is only five years and it affects both adults and children as young as two years old.¹ For those who are fortunate enough to receive a kidney transplant, approximately 60% will get re-occurring FSGS in the transplanted kidney.² At this time, there are no drugs specifically approved for FSGS anywhere in the world, so the treatment options and prognosis are limited. FSGS is a billion-dollar plus market: the number of people with FSGS in the US alone is just over 80,000,¹ and worldwide about 220,000.³ The illness has a global compound annual growth rate of 8%, with over 5,400 new

cases diagnosed in the US alone each year.⁴ Because there is no effective treatment, Dimerix has received Orphan Drug Designation for DMX 200 in both the US and Europe for FSGS. Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for various development incentives including: seven years (FDA) and ten years (EMA) of market exclusivity if regulatory approval is received, exemption from certain application fees, and a fast-tracked regulatory pathway to approval. Dimerix reported positive Phase 2a data in FSGS patients in July 2020.

References

- 2 Front. Immunol., (July 2019) | https://doi.org/10.3389/fimmu.2019.01669
- 3 Delve Insight Market Research Report (2022): Focal segmental glomerulosclerosis (FSGS) Market Insight, Epidemiology and market forecast – 2032; https://www.delveinsight.com/report-store/focal-segmentalglomerulosclerosis-fsgs-market;
- 4 Nephcure Kidney International (2020); Focal Segmental Glomerulosclerosis, online https://nephcure.org/livingwithkidneydisease/understanding-glomerular-disease/understanding-fsgs/

¹ Guruswamy Sangameswaran KD, Baradhi KM. (2021) Focal Segmental Glomerulosclerosis), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/



BIO CONNECTIONS AUSTRALIA 2024

Positioning for Success: Australian Biotech

Bio Connections 29 July 2024

Developing new therapies to treat inflammatory causes of kidney and respiratory disease with unmet clinical needs

Authorised for lodgement by the Board of the Company

Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.



Corporate overview

Ticker Symbol	ASX: DXB	
Cash Balance (Jun24)*	~A\$22.1 million	
Market Capitalisation ²	~A\$267 million	
Share price ¹	~A\$0.48	
Total ordinary shares on issue ²	550,659,795	
Average Daily Liquidity by value for past 30 trading days ²	~\$3.62 million	

* Cash balance includes payment of:

• significant one-off milestone payment for completion of Part 1 to IQVIA (*\$8.8 million of total prior quarter spend);

Cash balance does not include anticipated receipts of:

• ~AU\$500,000 up-front payment from Taiba partnership;

- FY24 R&D tax rebate; or
- Conversion of 49,625,053 DXB options currently exercisable at 15.4c per share with an expiry of 30 June 2025



SUBSTANTIAL SHAREHOLDERS³

Position	Holder Name	Holding	% IC
1	Mr P Meurs	75,304,506	13.7%
TOTAL (TOP 5) Shareholders		124,364,234	22.6%



3

DIMERIX - IN CONTEXT



A biopharmaceutical company developing innovative new therapies in areas of unmet medical needs



Currently advancing glabal Phase 3 edinical study in kidney disease




Overview Phase 3 Global Opportunity



Lead Drug Candidate

- DMX-200 is currently in a Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS)
- DMX-200 has orphan drug designation in key territories



FSGS Indication

- FSGS is a rare disease that causes scar tissue of kidneys, which leads to irreversible kidney damage¹
- FSGS kidney damage can lead to dialysis, kidney transplants or death¹
- There are currently no approved treatments available to treat FSGS



Commercial Validation

- Two commercial licensing deals achieved:
 - ~AU\$11.5m in upfront payments, ~AU\$340m in potential milestone payments + tiered royalties²
- Successful Phase 3 interim analysis: DMX-200 is performing better than placebo in reducing proteinuria³




Focal Segmental Glomerulosclerosis (FSGS)

What is FSGS?

Focal	= some
Segmental	= sections
Glomerulo	= of the kidney filtering units
Sclerosis	= are scarred

How do you measure kidney function?

- Historically, measured using "hard" endpoints for kidney disease
 (kidney failure) -which may not be reached for decades¹
- Regulatory agencies and national bodies now consider estimated glomerular filtration rate (eGFR) and proteinuria decline as surrogate end points for kidney failure in certain conditions²







1. Hartung E, (2015), Pediatric Nephrology volume 31, pages381–391 DOI: 10.1007/s00467-015-3104-8; 2. Thompson A et al, (2019) Am J Kidney Dis.; 75(1):4-5: doi.org/10.1053/j.ajkd.2019.08.007; 3. Nephcure FSGS living with the disease (2024) at https://nephcure.org/livingwithkidneydisease/ns-and-other-glomerular-diseases/understanding-fsgs/

Primary endpoint: proteinuria

Why are kidneys important?

A healthy kidney is a good filter and allows little to no protein in the urine¹

Inside a healthy kidney



= Protein
 (protein in the urine = proteinuria)

Inside a *damaged* kidney

Why is proteinuria important?

When kidneys are damaged, protein can leak into the urine causing proteinuria, hence proteinuria can represent an important early marker of kidney function²






little / no proteinuria suggests healthy kidney

DMX-200 aims to reduce the inflammation of the kidneys: if DMX-200 reduces inflammation = the amount of proteinuria should decrease

Proteinuria: an important endpoint for DMX-200 study

Average reduction of **17%** in proteinuria after **16** weeks treatment on DMX-200 versus placebo¹




"Any reduction in proteinuria could yield years of preserved native kidney function and delay the onset of kidney failure and its attendant morbidity and mortality" *Kidney survival study – Troost et al, August 2020*³



1. Nephcure FSGS living with the disease (2024) at https://nephcure.org/livingwithkidneydisease/ns-and-other-glomerulardiseases/understanding-fsgs/ 2. Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis (July 2021), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/; 3. Troost JP et al (August 2020); doi.org/10.1053/j.ajkd.2020.04.014

7

Primary endpoint: eGFR (kidney function) - example



Dimerix


8






9

A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB



Potential to submit for conditional marketing approval*






A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB

Recruitment planned at 170+ sites in:

- Australia, New Zealand •
- Taiwan, Hong Kong, Malaysia, Thailand •
- Mainland China
- France, Denmark, UK, Spain, Italy, ۲ Germany, Portugal
- Türkiye
- USA, Mexico •
- Argentina, Brazil


















CHALLENGES TO SUCCESS ALONG THE WAY



Three "valleys of death"

Good companies/technologies can fail:

- Lack of funding
- Lack of experienced team


👉 Dimerix

Funding pathway in place

Experienced team across all


phases of development &

commercialisation paradigm



- Does the science work?
- How is it funded?






GETTING OUR DUCKS IN A ROW



Competitive positioning summary

•Clinical studies play large part in the commercialisation plan but are by no means the only piece of the puzzle •In due diligence: everything here was reviewed in the **Dimerix dataroom!**

Container closure, shelf-life & product presentation





Slide from Bioshares 2019: We did exactly what we said we would do




👉 Dimerix

Time to deal

The time from first meeting to executing a license agreement takes time - it can take up to 2 years It is all in the planning and experience in doing deals:

- Structure, tactics & outreach
- Process management
- Negotiation and execution







DIMERIX - IN DEAL MAKING MODE



Global partnering trends – Q1 2024

R&D Partnerships – Global Healthcare and Life Sciences¹

Total Deal Value (\$B) Total Upfront Cash and Equity (\$B) - Number of Deals

\$80.0 350 \$73.0 \$70.0 300 \$62.3 \$60.0 \$56.8 250 \$50.4 \$50.0 \$46.6 \$44.3 200 \$40.2 \$39.6 \$38.5 \$38.0 \$40.0 \$32.9 \$36.6 \$36.4 \$36.0 \$35.7 150 \$31.1 \$30.1 \$29.1 \$30.0 \$25.3 \$21.9 100 \$20.0 50 \$8.2 \$10.0 \$7.4 \$6.4 \$5.4 \$4.0 \$3.7 \$3.9 \$3.4 \$3.4 \$3.4 \$3.1 \$3.1 \$2. \$2.6 \$2.2 \$2.0 \$2.2 \$1.4 \$1.4 \$0.0 Q2 Q3 Q3 Q2 Q3 Q4 Q1 Q2 Q3 Q1 Q1 Q4 Q1 Q2 Q4 Q1 Q2 03 Q4 Q1 Q4 2019 2023 2020 2021 2022 2024 Source: DealForma Database DEALFORMA Copyright © 2024 DealForma, LLC. All rights reserved.

The total number of deals across the sectors is declining²

- 2023 and Q1 2024 dealmaking environment shows fewer, but highervalue, transactions³
- Pharma is placing bigger bets on fewer, later stage and more strategic assets and platforms³



1. Healthcare & Life Sciences Quarterly Overview – Q1 2024, DealForma database : https://dealforma.com/healthcare-life-sciences-quarterly-overview-q1-2024/
 2. JP Morgan Q1 2024 Biopharma Licensing and Venture Report: www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpm-biopharma-deck-q1-final.pdf;
 3. Clarivate, Pharma is placing bigger bets on fewer, more strategic assets and platforms, May 2024: https://clarivate.com/blog/pharma-is-placing-bigger-bets-on-fewer-morestrategic-assets-and-platforms/

20


Kidney disease is high interest area for pharma

Kidney disease is the third-fastest-growing cause of death globally¹

- In the US alone, the number of people with kidney failure increased by >200% from 2001 to 2023²
- By 2040, it is expected to become the fifth-highest cause of years of life lost^{1,2}

The US government-funded health-care plan (Medicare) spent US\$130 billion in 2023 to treat kidney disease patients

• the majority being on dialysis^{1,3}



Prevalence of Kidney Failure, 2001-2023²



1. Editorial, Time to sound the alarm about the hidden epidemic of kidney disease, Nature 628, 7-8 (2024) doi: https://doi.org/10.1038/d41586-024-00961-5; 2. The United States Renal Data System (USRDS) Annual Report 2023; (2022 & 2023 estimates based on average growth 2001-2021) 3. Francis et al. (2024), Nature Rev. Nephrol. https://doi.org/10.1038/s41581-024-00820-6

Summary of DMX-200 licensing deals

Dimerix has validated the technology¹ and proven its ability to licence multiple territories, with more deals anticipated

Summary	PHARMA 2	³ cccess rare	Other Licensing Deals (incl. US & China)	Dimerix has achieved up to AU\$350 million ^{2,3} in upfront payments and	
Territories Covered	EEA, Canada, Switzerland, UK, Australia and New Zealand	United Arab Emirates (UAE), Saudi Arabia, Oman, Kuwait, Qatar, Bahrain and Iraq	?	potential milestones payments from two licensing deals	
Upfront Payment	~AU\$10.8 million	~AU\$500,000	?		
Milestone Payments	Up to ~AU\$219 million	Up to ~AU\$120 million	?	Major focus on US & China which, collectively,	
Royalties on net sales	Escalating mid-teen-20%	Starting at 30%	?	could represent ~70% of the global value ⁴	




Summary Phase 3 Global Opportunity



23


Lead Drug Candidate

- DMX-200 is currently in a Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS)
- DMX-200 has orphan drug designation in key territories



FSGS Indication

- FSGS is a rare disease that causes scar tissue of kidneys, which leads to irreversible kidney damage¹
- FSGS kidney damage can lead to dialysis, kidney transplants or death¹
- There are currently no approved treatments available to treat FSGS



Commercial Validation

- Two commercial licensing deals achieved:
 - ~AU\$11.5m in upfront payments, ~AU\$340m in potential milestone payments + tiered royalties²
- Successful Phase 3 interim analysis: DMX-200 is performing better than placebo in reducing proteinuria³





A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases.

WELL POSITIONED TO DELIVER OUR STRATEGIC PLAN



Dimerix HQ 425 Smith St, Fitzroy 3065 Victoria, Australia T. 1300 813 321 E. investor@dimerix.com

ESG Statement

Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.